944718-10-9

Basic information

• Product Name: 2-BROMOMETHYL-6-METHOXYISOINDOLINONE
• Synonyms: 2-BROMOMETHYL-6-METHOXYISOINDOLINONE;2-Bromomethyl-6-methoxy-2,3-dihydro-isoindol-1-one;2-(BroMoMethyl)-6-Methoxyisoindolin-1-one
• CAS NO: 944718-10-9
• Molecular Formula: C10H10BrNO2
• Molecular Weight: 256.11
• Mol File: 944718-10-9.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 392.1°C at 760 mmHg
• Flash Point: 190.9°C
• Appearance: /
• Density: 1.558g/cm³
• Vapor Pressure: 2.35E-06mmHg at 25°C
• Refractive Index: 1.605
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2-BROMOMETHYL-6-METHOXYISOINDOLINONE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-BROMOMETHYL-6-METHOXYISOINDOLINONE(944718-10-9)
• EPA Substance Registry System: 2-BROMOMETHYL-6-METHOXYISOINDOLINONE(944718-10-9)

Safety Data

• Hazardous Substances Data: 944718-10-9(Hazardous Substances Data)

Usage

General Description

2-BROMOMETHYL-6-METHOXYISOINDOLINONE is a chemical compound with the molecular formula C9H8BrNO2. It is a brominated isoindolinone derivative that has a methoxy group attached to the sixth position. The compound is primarily used as an intermediate in the synthesis of pharmaceuticals and other organic compounds. It has been studied for its potential pharmacological properties and has shown to possess anti-inflammatory and analgesic effects. Additionally, it has been used in chemical research as a building block for the synthesis of various heterocyclic compounds. Overall, 2-BROMOMETHYL-6-METHOXYISOINDOLINONE is a versatile chemical with potential applications in the pharmaceutical and chemical industries.

InChI:InChI=1/C10H10BrNO2/c1-14-8-3-2-7-5-12(6-11)10(13)9(7)4-8/h2-4H,5-6H2,1H3

Upstream product

• 35450-36-3 methyl 2-bromo-5-methoxybenzoate 
• 22246-66-8 6-methoxy-2,3-dihydro-isoindol-1-one 
• 788081-99-2 methyl 2-(bromomethyl)-5-methoxy-benzoate 
• 73502-03-1 methyl 5-methoxy-2-methyl-benzoate 
• 944718-09-6 2,2-Dimethyl-propionic acid 6-methoxy-1-oxo-1,3-dihydro-isoindol-2-ylmethyl ester 

Downstream Products

• 944718-26-7 (R)-2-Methoxycarbonylamino-2-(6-methoxy-1-oxo-1,3-dihydro-isoindol-2-ylmethyl)-4-(4-sulfo-phenyl)-but-3-ynoic acid methyl ester 

Relevant articles and documents

Synthesis of [3H], [13C3, 15N], and [14C]SCH 900567: An inhibitor of TNF-α (tumor necrosis factor alpha) converting enzyme (TACE)

SCH 900567 is a specific inhibitor of tumor necrosis factor-alpha converting enzyme and is a potential candidate for the treatment of rheumatoid arthritis. [3H]SCH 900567 was synthesized to support the initial drug metabolism and pharmacokinetics studies. Stable isotope-labeled [13C3, 15N]SCH 900567 was requested by the bioanalytical group as an internal standard for Liquid chromatography-tandem mass spectrometry (LC-MS/MS) method development as well as by the drug metabolism and pharmacokinetics group for a potential microdose study. [13C3, 15N]SCH 900567 is synthesized via a linear sequence of seven steps from commercially available materials in 2.6% overall yield. [14C]SCH 900567 was needed for a quantitative whole body autoradiography studies and was prepared from unlabeled Active Pharmaceutical Ingredient (API) via hydrolysis of the hydantoin moiety followed by rebuilding the hydantoin ring using potassium [14C]cyanate to give the desired product in 42.8% overall yield. Activation of the hydantoin moiety of SCH 900567 to achieve hydrolysis followed by derivatization of the resulting amino acid to avoid decarboxylation during cyclization is also discussed.

Novel TNF-α converting enzyme (TACE) inhibitors as potential treatment for inflammatory diseases

Our research on hydantoin based TNF-α converting enzyme (TACE) inhibitors has led to an acetylene containing series that demonstrates sub-nanomolar potency (Ki) as well as excellent activity in human whole blood. These studies led to the discov

HYDANTOIN DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISORDERS

This invention relates to compounds of the Formula: (I); or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF-α or combinations thereof.